J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win
Johnson & Johnson said that its combination treatment staved off cancer progression for longer than AstraZeneca’s blockbuster Tagrisso as a first option for patients with a form of advanced lung cancer.
In the Phase III MARIPOSA study, J&J pitted its bispecific antibody Rybrevant and tyrosine kinase inhibitor lazertinib against Tagrisso alone. The study included 1,074 patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.